BACKGROUND: @entity3413 , 20mg, plus @entity3709 , 10mg, daily ( @entity3413 plus @entity3709 ) reduced major @entity731 events in @entity1 with moderate to severe @entity740 ( @entity740 ) in the Study of Heart and Renal Protection (SHARP), but its cost-effectiveness is unknown. STUDY DESIGN: Cost-effectiveness of @entity3413 plus @entity3709 in SHARP, a randomized controlled trial. SETTING _ POPULATION: 9,270 @entity1 with @entity740 randomly assigned to @entity3413 plus @entity3709 versus placebo; @entity1 in categories by 5-year cardiovascular risk (low,  <10%; medium, 10%-<20%; or high,  >= 20%) and @entity740 stage (3, 4, 5 not on dialysis, or on dialysis therapy). MODEL, PERSPECTIVE, _ TIMELINE: Assessment during SHARP follow-up from the UK perspective; long-term projections. INTERVENTION: @entity3413 plus @entity3709 (2015 UK   1.19 per day) during 4.9 years' median follow-up in SHARP; scenario analyses with high-intensity statin regimens (2015 UK   0.05-  1.06 per day). OUTCOMES: Additional health care costs per major @entity731 event avoided and per quality-adjusted life-year (QALY) gained. RESULTS: In SHARP, the proportional reductions per 1mmol/L of low-density lipoprotein (LDL) @entity165 reduction with @entity3413 plus @entity3709 in all major @entity731 events of 20% (95% CI, 6%-32%) and in the costs of vascular hospital episodes of 17% (95% CI, 4%-28%) were similar across @entity1 categories by cardiovascular risk and @entity740 stage. The 5-year reduction in major @entity731 events per 1,000 @entity1 ranged from 10 in low-risk to 58 in high-risk @entity1 and from 28 in @entity740 stage 3 to 36  in @entity1 on dialysis therapy. The net cost per major @entity731 event avoided with @entity3413 plus @entity3709 compared to no LDL-lowering regimen ranged from   157,060 in @entity1 at low risk to   15,230 in those at high risk (  30,500-  39,600 per QALY); and from   47,280 in @entity740 stage 3 to   28,180 in @entity1 on dialysis therapy (  13,000-  43,300 per QALY). In scenario analyses, generic high-intensity statin regimens were estimated to yield similar benefits at substantially lower cost. LIMITATIONS: High-intensity statin-alone regimens were not studied in SHARP. CONCLUSIONS: @entity3413 plus @entity3709 prevented @entity731 events in SHARP, but other less costly statin regimens are likely to be more cost-effective for reducing cardiovascular risk in @entity740 .

Cost-effectiveness of @entity3413 plus XXXX for Cardiovascular Prevention in @entity740 : Results of the Study  of  Heart  and Renal Protection (SHARP).

@entity1 :: ('9606', 'Species') :: ['participants', 'patients', 'participant'] @entity3413 :: ('MESH:D019821', 'Chemical') :: ['Simvastatin', 'simvastatin'] @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease'] @entity3709 :: ('MESH:C108606', 'Chemical') :: ['ezetimibe'] @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity3709 :: (MESH:C108606,Chemical) :: ['Ezetimibe']
